These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 22437319)

  • 1. The mutation profiles of common oncogenes involved in melanoma in southern China.
    Zhou QM; Li W; Zhang X; Chen YB; Chen XC; Guan YX; Ding Y; Wen XZ; Xia Q; Zhou Q; Peng RQ; Hou JH; Zhu XF; Zeng YX; Zhang XS
    J Invest Dermatol; 2012 Jul; 132(7):1935-7. PubMed ID: 22437319
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutations in ERBB4 may have a minor role in melanoma pathogenesis.
    Manca A; Lissia A; Cossu A; Rubino C; Ascierto PA; Stanganelli I; Palmieri G
    J Invest Dermatol; 2013 Jun; 133(6):1685-7. PubMed ID: 23340734
    [No Abstract]   [Full Text] [Related]  

  • 3. Mutated ERBB4: a novel drug target in metastatic melanoma?
    Kurppa K; Elenius K
    Pigment Cell Melanoma Res; 2009 Dec; 22(6):708-10. PubMed ID: 19735458
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas.
    Niu HT; Zhou QM; Wang F; Shao Q; Guan YX; Wen XZ; Chen LZ; Feng QS; Li W; Zeng YX; Zhang XS
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):646-53. PubMed ID: 23751074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel putative receptor tyrosine kinase encoded by the melanoma-inducing Tu locus in Xiphophorus.
    Wittbrodt J; Adam D; Malitschek B; Mäueler W; Raulf F; Telling A; Robertson SM; Schartl M
    Nature; 1989 Oct; 341(6241):415-21. PubMed ID: 2797166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical markers and driving mechanisms in melanoma progression: VEGF-C, RhoC, c-Ski/SnoN and EGFR.
    Boone B; Brochez L
    Verh K Acad Geneeskd Belg; 2009; 71(5):251-94. PubMed ID: 20232784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor.
    Mueller BM; Romerdahl CA; Trent JM; Reisfeld RA
    Cancer Res; 1991 Apr; 51(8):2193-8. PubMed ID: 2009538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR in melanoma: clinical significance and potential therapeutic target.
    Boone B; Jacobs K; Ferdinande L; Taildeman J; Lambert J; Peeters M; Bracke M; Pauwels P; Brochez L
    J Cutan Pathol; 2011 Jun; 38(6):492-502. PubMed ID: 21352258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.
    Settleman J
    Cancer Cell; 2009 Oct; 16(4):278-9. PubMed ID: 19800573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No evidence for ErbB4 gene amplification in malignant melanoma.
    Brockhoff G; Bock M; Gantner S; Hafner C
    Acta Derm Venereol; 2011 Jun; 91(4):488-90. PubMed ID: 21547347
    [No Abstract]   [Full Text] [Related]  

  • 11. The classification of cutaneous melanoma.
    Duncan LM
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):501-13, ix. PubMed ID: 19464599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. neu proto-oncogene mutation is specific for the neurofibromas in a N-nitroso-N-ethylurea-induced hamster neurofibromatosis model but not for hamster melanomas and human Schwann cell tumors.
    Nakamura T; Ushijima T; Ishizaka Y; Nagao M; Nemoto T; Hara M; Ishikawa T
    Cancer Res; 1994 Feb; 54(4):976-80. PubMed ID: 7906199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenes in melanoma: an update.
    Kunz M
    Eur J Cell Biol; 2014; 93(1-2):1-10. PubMed ID: 24468268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse pigmentation mutants help identify a uveal melanoma oncogene.
    Hayward NK
    Pigment Cell Melanoma Res; 2009 Feb; 22(1):2-3. PubMed ID: 19140886
    [No Abstract]   [Full Text] [Related]  

  • 15. [Regulation of melanoma growth].
    Paloheimo M; Saksela O; Pyrhönen S; Alitalo K
    Duodecim; 1992; 108(23-24):2097-104. PubMed ID: 1345291
    [No Abstract]   [Full Text] [Related]  

  • 16. Oncogenes in head and neck cancer.
    Irish JC; Bernstein A
    Laryngoscope; 1993 Jan; 103(1 Pt 1):42-52. PubMed ID: 8421418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53.
    Chenevix-Trench G; Martin NG; Ellem KA
    Oncogene; 1990 Aug; 5(8):1187-93. PubMed ID: 1697409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
    Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
    Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma.
    Balakrishnan A; Bleeker FE; Lamba S; Rodolfo M; Daniotti M; Scarpa A; van Tilborg AA; Leenstra S; Zanon C; Bardelli A
    Cancer Res; 2007 Apr; 67(8):3545-50. PubMed ID: 17440062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
    Weiner DB; Liu J; Cohen JA; Williams WV; Greene MI
    Nature; 1989 May; 339(6221):230-1. PubMed ID: 2654648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.